InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx's anti-C5a Technology

Stock Information for InflaRx N.V.

Loading

Please wait while we load your information from QuoteMedia.